New monoclonal antibodies in targeted therapy of allergic diseases
https://doi.org/10.37489/2949-1924-0097
EDN: OIXFRG
Abstract
Monoclonal antibodies have significantly expanded the therapeutic options for severe allergic diseases by targeting key mechanisms in their pathogenesis. This review briefly presents data on the efficacy and safety of monoclonal antibodies that are not registered in the Russian Federation but have successfully completed late-stage clinical trials or have been approved by the U. S. FDA for the treatment of asthma, atopic eczema, allergic rhinitis, eosinophilic esophagitis, food allergy and chronic spontaneous urticaria. Further research is needed to evaluate their long-term safety, along with efforts to address registration challenges and to make these drugs more accessible for routine medical practice in the Russian Federation.
Supporting agencies: The work was carried out without sponsorship
About the Authors
T. I. Pushkina
Yaroslavl State Medical University
Russian Federation
Competing Interests:
Russian Federation
Tatyana I. Pushkina, Resident pediatrician of 2 year of study
Department of Pediatrics
Yaroslavl
Competing Interests:
Authors declare no conflict of interest requiring disclosure in this article
L. G. Emelicheva
Yaroslavl State Medical University
Russian Federation
Competing Interests:
Russian Federation
Lidiya G. Emelicheva, Cand. Sci. (Med.), Associate Professor
Department of Pediatrics
Yaroslavl
Competing Interests:
Authors declare no conflict of interest requiring disclosure in this article
References
1. Tanno LK, Chalmers R, Jacob R, et al. Global implementation of the world health organization's International Classification of Diseases (ICD)-11: The allergic and hypersensitivity conditions model. Allergy. 2020 Sep;75(9):2206-18. doi: 10.1111/all.14468.
2. Zhang L, Akdis CA. The past, present, and future of allergic diseases in China. Allergy. 2022 Feb;77(2):354-6. doi: 10.1111/all.15213.
3. Atanasio A, Orengo JM, Sleeman MA, et al. Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities. Front Allergy. 2022 Oct 24;3:1019255. doi: 10.3389/falgy.2022.1019255.
4. Eggel A, Pennington LF, Jardetzky TS. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways. Immunol Rev. 2024 Nov;328(1):387-411. doi: 10.1111/imr.13380.
5. State Register of Medicines [Internet]. Instructions for medical use of the drug Xolair. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx-?routingGuid=e582b714-e6f9-463d-8530-f5542a7bd995.
6. State Register of Medicines [Internet]. Instructions for medical use of the drug Dupixent. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx-?routingGuid=feae14bc-d775-4190-ae20-9db94eeb6547.
7. State Register of Medicines [Internet]. Instructions for medical use of the drug Fasenra. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx-?routingGuid=16014be9-403e-489a-b6e2-d3cf49bb8d00.
8. State Register of Medicines [Internet]. Instructions for medical use of the drug Sinqueiro. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx-?routingGuid=348da3af-90d2-4df8-81ce-08619994d810.
9. State Register of Medicines [Internet]. Instructions for medical use of the drug Nucala. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routing-Guid=b7a6f6cf-2e9c-4718-91c9-442c9c294777.
10. State Register of Medicines [Internet]. Instructions for medical use of the drug Tesspire. https://grls.minzdrav.gov.ru/Grls_View_v2.as-px?routingGuid=c527f7f4-67a7-4bfb-9a8b-c5b-5f08059ee.
11. Morita H, Matsumoto K, Saito H. Biologics for allergic and immunologic diseases. J Allergy Clin Immunol. 2022 Oct;150(4):766-77. doi: 10.1016/j.jaci.2022.08.009.
12. Russo D, Di Filippo P, Di Pillo S, et al. New Indications of Biological Drugs in Allergic and Immunological Disorders: Beyond Asthma, Urticaria, and Atopic Dermatitis. Biomedicines. 2023 Jan 17;11(2):236. doi: 10.3390/biomedicines11020236.
13. Global Initiative for Asthma [Интернет]. Global strategy for asthma management and prevention [2025 May 6]. Режим доступа: https://ginasthma.org/wp-content/uploads/2025/05/GINA-Strategy-Report_2025-WEB-WMS.pdf. Дата обращения: 17. 05. 2025.
14. Laorden D, Domínguez-Ortega J, Romero D, et al. Efficacy Assessment of Biological Treatments in Severe Asthma. J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.
15. Gyawali B, Georas SN, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025 Jan 8;34(175):240088. doi: 10.1183/16000617.0088-2024.
16. Seluk L, Davis AE, Rhoads S, et al. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025 Jan;134(1):9-18. doi: 10.1016/j.anai.2024.09.016.
17. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024 Dec;391(24):2337-49. doi: 10.1056/NEJ-Moa2406673.
18. GSK [Интернет]. Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP) [2025 Mar 3]. Режим доступа: https://www.gsk.com/en-gb/media/press-releases/depemokimab-applications-accepted-for-review-by-the-us-fda/. Дата обращения: 17. 05. 2025.
19. Corren J, Szefler SJ, Sher E, et al. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May;12(5):1215-24.e3. doi: 10.1016/j.jaip.2024.02.007.
20. Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-8. doi: 10.1016/j.jaci.2021.03.044.
21. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-68. doi: 10.1056/NEJMoa2024257.
22. Corren J, Reid F, Moate R, et al. S90 FRONTIER-3: a randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma. Thorax. 2024 Nov 3;79:A65-A66. doi: 10.1136/thorax-2024-BTSabstracts.96.
23. Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025 May 2;00:1-30. doi: 10.1111/jdv.20639.
24. Salman A, Giménez-Arnau AM. Emerging Systemic Treatment Options in Atopic Dermatitis. Balkan Med J. 2024 Jul 5;41(4):239-47. doi: 10.4274/balkanmedj.galenos.2024.2024-5-78.
25. Silverberg JI, Strober B, Feinstein B, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol. 2024 Apr;153(4):1040-9.e12. doi: 10.1016/j.jaci.2023.11.924.
26. Zhao Y, Zhang L, Zhang J; CM310AD005 Study Investigators. Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2024 Nov;91(5):984-6. doi: 10.1016/j.jaad.2024.07.1447.
27. Zhao Y, Zhang L, Wu L, et al. Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Allergy. 2024 Oct 25. doi: 10.1111/all.16368.
28. ADBRY (tralokinumab): prescribing information [Интернет]. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761180s006lbl.pdf. Дата обращения: 19. 05. 2025.
29. Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021 Mar;184(3):450-63. doi: 10.1111/bjd.19573.
30. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-49. doi: 10.1111/bjd.19574.
31. Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA dermatol. 2023 Jun 1;159(6):596–605. doi: 10.1001/jamadermatol.2023.0627.
32. Calabrese L, Cinotti E, D'Onghia M, et al. Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study. Acta Derm Venereol. 2025 Mar 12. doi: 10.2340/actadv.v105.42275.
33. George SE, Yu J. Tralokinumab as an effective alternative after dupilumab treatment failure in moderate-to-severe atopic dermatitis: A real-world study. J Am Acad Dermatol. 2024 Dec;91(6):1228-30. doi: 10.1016/j.jaad.2024.08.019.
34. Chovatiya R, Ribero S, Wollenberg A, et al. Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years. Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.
35. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023 May 24;188(6):740-8. doi: 10.1093/bjd/ljad022.
36. EBGLYSS (lebrikizumab): prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761306Orig1s000correctedlbl.pdf.
37. Blauvelt A, Guttman-Yassky E, Lynde C, et al. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Jul 17;160(8):856-64. doi: 10.1001/jamadermatol.2024.2131.
38. Alvarenga JM, Bieber T, Torres T. Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. 2024 Nov;84(11):13-1394. doi: 10.1007/s40265-024-02095-4.
39. Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024 Aug 3;404(10451):445-60. doi: 10.1016/S0140-6736(24)01203-0.
40. NEMLUVIO (nemolizumab): prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761391s000lbl.pdf.
41. Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025 Apr;155(4):1264-75. doi: 10.1016/j.jaci.2024.10.031.
42. Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-14. doi: 10.1016/S0140-6736(22)02037-2.
43. Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Glob. 2023 Nov 22;3(1):100195. doi: 10.1016/j.jacig.2023.100195.
44. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023 Apr;13(4):293-859. doi: 10.1002/alr.23090.
45. Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 Jul;142(1):171-7.e1. doi: 10.1016/j.jaci.2017.11.051.
46. Zhang Y, Li J, Wang M, et al. Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial. Nat Med. 2025 Apr 4. doi: 10.1038/s41591-025-03651-5.
47. Yang B, Li W, Gao Y, et al. Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis in Humans: A Scoping Review. Biomedicines. 2024 Nov 11;12(11):2576. doi: 10.3390/biomedicines12112576.
48. Dellon ES, Charriez CM, Zhang S, et al. 43, Cendakimab Efficacy and Safety in Adult and Adolescent Patients With Eosinophilic Esophagitis: 48-Week Results From the Randomized, Placebo-Controlled, Phase 3 Study (late-breaking abstract), ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
49. Sindher SB, Hillier C, Anderson B, et al. Treatment of food allergy: Oral immunotherapy, biologics, and beyond. Ann Allergy Asthma Immunol. 2023 Jul;131(1):29-36. doi: 10.1016/j.anai.2023.04.023.
50. Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018 Feb; 3(2):85-94. doi: 10.1016/S2468-1253(17)30392-8.
51. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Mar 7;390(10):889-99. doi: 10.1056/NEJMoa2312382
Review
For citations:
Pushkina T.I., Emelicheva L.G. New monoclonal antibodies in targeted therapy of allergic diseases. Patient-Oriented Medicine and Pharmacy. 2025;3(3):10-20. (In Russ.) https://doi.org/10.37489/2949-1924-0097. EDN: OIXFRG
Views:
65
.png)
Email this article 